Hundreds of France-based Lactalis baby formula milk and baby products under brands such as Celia, Picot and Milumel were ordered to be removed from shelves around the world because of the presence of salmonella bacteria that has sickened 26 infants. Some of the formula products were scheduled for export to Greece, China, Peru and Pakistan.
There were two themes among the most successful medical device companies this year: innovation and breadth of services. This was the major takeaway of an MDO analysis of the stock performance of the 100 largest publicly traded medtech companies in the world. What does innovation mean? Think Align Technologies and how it brought 3D printing to bear on a dental product screaming for better customization: braces. Or there's Abiomed and its tiny Impella heart pump, which is meant to help restore blood flow and allow the heart to rest after a heart attack. For breadth of services, look no further than Integer, a giant medical device contract manager created out of the 2015 merger of Greatbatch and Lake Region Medical. Go to Medical Design & Outsourcing to find out more about the 10 best-performing medtech stocks of 2017.
The FDA approved Sanofi's Admelog, or insulin lispro injection, as a treatment for adults with type 1 and type 2 diabetes and children with type 1 diabetes. Admelog has been approved as the first follow-on biologic version of Humalog, Eli Lilly and Co.'s fast-acting insulin.
Data presented at the meeting of the American Society of Hematology last week by bluebird bio and Celgene researchers on their chimeric antigen receptor T-cell therapy candidate bb2121 showed the therapy achieved a 94% response rate from 18 patients with advanced multiple myeloma, with 56% maintaining remission 40 weeks after treatment on average.
AstraZeneca disclosed details on data from its clinical trial to assess the efficacy of its drug candidate Calquence as a treatment for mantle cell lymphoma, which showed its efficacy and resulted in fewer side effects compared with the current standard of care. GSK was also scheduled to publish a study on the effectiveness of its multiple myeloma antibody treatment GSK 2857916, according to presentations made at the American Society of Hematology last week.
The Commitment to Partnership in Addressing HIV/AIDS in Southern States, or COMPASS, Initiative was launched by Gilead Sciences with $100 million over a 10-year span to help combat HIV/AIDS in the Southern United States. Gilead is partnering with Emory University's Rollins School of Public Health, the SUSTAIN Wellbeing COMPASS Coordinating Center at the University of Houston and the Southern AIDS Coalition, which will identify and propose funding for Southern community groups that fight the disease.
The Defense Advanced Research Projects Agency's Advanced Plant Technologies program is developing a way to manipulate the physiology of plants so they can be used to detect chemical and bioweapons. "Because plants naturally respond to many categories of stimuli, we believe that they can serve as sensitive detectors for many [Department of Defense]-relevant threats," said Dr. Blake Bextine, manager of the Advanced Plant Technologies program.
A team of University of Calgary researchers developed a way to turn human waste into bioplastic, which can be useful to space travelers in recycling their wastes. The volatile fatty acids in the human waste were consumed by engineered bacteria that secrete plastics as a byproduct.
Teva launched its sildenafil citrate tablets, a generic version of Pfizer's Viagra, in the United States. The tablets are intended to treat patients with erectile dysfunction.
Eli Lilly and Co.'s marketing application for galcanezumab, a prefilled syringe for the treatment of migraine in adults, was accepted by the FDA for review.
- Page 1